In 2019, there were 6.5 million deaths from stroke worldwide. Stroke is a leading cause of serious long-term disability in the US and worldwide.[16]GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820.
https://www.doi.org/10.1016/S1474-4422(21)00252-0
http://www.ncbi.nlm.nih.gov/pubmed/34487721?tool=bestpractice.com
[190]Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics - 2021 update: a report from the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743.
https://www.doi.org/10.1161/CIR.0000000000000950
http://www.ncbi.nlm.nih.gov/pubmed/33501848?tool=bestpractice.com
Prognosis of functional outcome can be reliably performed by well-validated prognostic scores like the ASTRAL score or the iScore.[191]Cooray C, Mazya M, Bottai M, et al. External validation of the ASTRAL and DRAGON scores for prediction of functional outcome in stroke. Stroke. 2016 Jun;47(6):1493-9.
https://www.ahajournals.org/doi/full/10.1161/strokeaha.116.012802
http://www.ncbi.nlm.nih.gov/pubmed/27174528?tool=bestpractice.com
Intravenous thrombolysis and dedicated stroke units are the only interventions shown to improve stroke outcome.
Common medical complications of stroke include aspiration pneumonia, depression, and deep vein thrombosis.
A meta-analysis study on the efficacy of physiotherapy following stroke found that a variety of interventions improved functional outcomes, even when they were applied late after stroke.[192]Ferrarello F, Baccini M, Rinaldi LA, et al. Efficacy of physiotherapy interventions late after
stroke: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):136-43.
http://www.ncbi.nlm.nih.gov/pubmed/20826872?tool=bestpractice.com
Patients receiving alteplase
Patients treated with alteplase (if given within 4.5 hours of onset of symptoms) have a better functional outcome than patients not treated with alteplase. There is, however, an increased risk of intracerebral haemorrhage with alteplase; this does not seem to affect death or dependency at 3 months.[63]Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29;(7):CD000213.
https://www.doi.org/10.1002/14651858.CD000213.pub3
http://www.ncbi.nlm.nih.gov/pubmed/25072528?tool=bestpractice.com
[125]Davis S, Holmes M, Simpson E, et al. Alteplase for the treatment of acute ischaemic stroke (review of technology appraisal 122): a single technology appraisal. School of Health and Related Research (ScHARR), University of Sheffield. May 2012 [internet publication].
https://www.nice.org.uk/guidance/ta264/documents/stroke-acute-ischaemic-alteplase-review-of-ta122-evidence-review-group-report2
[193]Hacke W, Lyden P, Emberson J, et al. Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: individual-patient-data meta-analysis of randomized trials. Int J Stroke. 2018 Feb;13(2):175-89.
https://www.doi.org/10.1177/1747493017744464
http://www.ncbi.nlm.nih.gov/pubmed/29171359?tool=bestpractice.com
Patients receiving tenecteplase
Tenecteplase within 4.5 hours of ischaemic stroke due to large vessel occlusion is non-inferior to alteplase in terms of excellent functional outcome (90-day modified Rankin Scale [mRS] scores of 0-1) and may be superior to alteplase in terms of good functional outcome (90-day mRS scores of 0-2), as supported by meta-analysis of several randomised controlled trials.[106]Alamowitch S, Turc G, Palaiodimou L, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023 Mar;8(1):8-54.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069183
http://www.ncbi.nlm.nih.gov/pubmed/37021186?tool=bestpractice.com
[118]Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017 Oct;16(10):781-8.
http://www.ncbi.nlm.nih.gov/pubmed/28780236?tool=bestpractice.com
[119]Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022 Jun;21(6):511-9.
http://www.ncbi.nlm.nih.gov/pubmed/35525250?tool=bestpractice.com
[120]Haley EC Jr, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010 Apr;41(4):707-11.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860601
http://www.ncbi.nlm.nih.gov/pubmed/20185783?tool=bestpractice.com
[121]Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023 Feb 25;401(10377):645-54.
http://www.ncbi.nlm.nih.gov/pubmed/36774935?tool=bestpractice.com
[122]Yogendrakumar V, Churilov L, Guha P, et al. Tenecteplase treatment and thrombus characteristics associated with early reperfusion: an EXTEND-IA TNK trials analysis. Stroke. 2023 Mar;54(3):706-14.
https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.122.041061
http://www.ncbi.nlm.nih.gov/pubmed/36727510?tool=bestpractice.com
Low-quality trial evidence suggests no significant differences in terms of mortality secondary to symptomatic intracerebral haemorrhage.[106]Alamowitch S, Turc G, Palaiodimou L, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023 Mar;8(1):8-54.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069183
http://www.ncbi.nlm.nih.gov/pubmed/37021186?tool=bestpractice.com
Tenecteplase is not recommended for patients with ischaemic stroke on awakening from sleep or of unknown onset who undergo no brain imaging other than computed tomography (CT). In a phase 3 randomised controlled trial of patients with wake-up stroke selected with non-contrast CT, treatment with tenecteplase was not associated with better functional outcome at 90 days versus the control group, and there was no difference in mortality between groups.[123]Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2023 Feb;22(2):117-26.
http://www.ncbi.nlm.nih.gov/pubmed/36549308?tool=bestpractice.com